Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC1641 Phase II Study Of Intratumoral Injection Of Autologous Dendritic Cells Combined With Immune Checkpoint Inhibition After High-Dose Conformal External Beam Radiotherapy In Patients With Unresectable Primary Liver Cancer

NCT03942328 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03942328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03942328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC1641 Phase II Study Of Intratumoral Injection Of Autologous Dendritic Cells Combined With Immune Checkpoint Inhibition After High-Dose Conformal External Beam Radiotherapy In Patients With Unresectable Primary Liver Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 19, 2019
Completion date
August 31, 2030
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii hepatocellular carcinoma ajcc v8, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8, unresectable hepatocellular carcinoma, unresectable intrahepatic cholangiocarcinoma